Acronym | AVITHRAPID |
Grant Agreement ID | 101137192 |
Implementation period | 01/01/2024 – 30/06/2028 |
Coordinator | Fraunhofer Society for the Advancement of Applied Research, Germany |
Call for proposal | HORIZON-HLTH-2023-DISEASE-03 |
Total Budget | € 7 459 253,75 (EU contribution € 7 459 253,75) |
Project participants | Latvian Institute of Organic Synthesis (LIOS), Latvia |
University of Tuscia, Italy | |
EuResist Network, Italy | |
Elettra Sincrotrone Trieste, Italy | |
University of Naples Federico II, Italy | |
First Health Pharmaceuticals, Netherlands | |
National Institute of Infectious Diseases Lazzaro Spallanzani, Italy | |
University of Siena, Italy | |
Instituto de Medicina Molecular João Lobo Antunes, Portugal | |
University of Cagliari, Italy | |
University of Tours, France | |
French National Institute of Health and Medical Research (3rd party) | |
Tor Vergata University of Rome, Italy | |
VSB – Technical University of Ostrava, Czechia | |
Dompe’ Farmaceutici – S.P.A., Italy | |
National Research Institute for Agriculture, Food and Environment, France | |
Partners | Swiss Tropical and Public Health Institute, Switzerland |
Chelonia SA, Switzerland | |
Project leader in LIOS | Prof. Aigars Jirgensons |
LIOS Budget | € 303 750.00 (EU contribution € 303 750.00) |
The European Consortium “Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases” (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches.
Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses. This will be achieved by combining the relevant expertise for pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus. Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets.
As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases.